Invesco Dynamic Biotechnology & Genome ETF Price & Performance (PBE)

Wells Fargo & Company MN trimmed its stake in the Invesco Biotechnology & Genome ETF by 1.7% in Q4, while other institutional players like JPMorgan Chase increased their exposure. The ETF opened at $59.03 recently, marking a notable retreat from its 52-week high of $72.84, reflecting shifting sentiment in biotech equities.12

The Invesco Biotechnology & Genome ETF has underperformed the S&P Composite 1500 Biotechnology Index year-to-date, posting a -4.53% return compared to the benchmark’s 12.23%. Its allocation remains heavily weighted toward small- and mid-cap biotech firms, with top holdings including Gilead Sciences and Amgen. Performance volatility remains a concern for investors.31

Recent analysis highlights PBE’s focus on pioneering biotech and genome companies, balancing established names with emerging innovators. Despite sector leadership, the ETF saw $12 million in net outflows over the past year, and its assets under management now stand at roughly $212 million. Sector-specific volatility continues to test investor conviction.43